Bacterial modification of the host glycosaminoglycan heparan sulfate modulates SARS-CoV-2 infectivity

Cameron Martino(University of California San Diego), Rob Knight(University of California San Diego), Se Jin Song(University of California San Diego), Lívia S. Zaramela(Universidade de Ribeirão Preto), Clarisse Marotz(University of California San Diego), Daniel McDonald(University of California San Diego), Yoshiki Vázquez‐Baeza(University of Colorado Boulder), Laxmi Parida(IBM (United States)), Susan Cheng(Cedars-Sinai Medical Center), James T. Sorrentino(University of California San Diego), Erick Armingol(Wellcome Sanger Institute), Chenguang Liang(University of California San Diego), Rodolfo Antonio Salido Benítez(University of California San Diego), Daniel R. Sandoval(University of California San Diego), Benjamin P. Kellman(Ragon Institute of MGH, MIT and Harvard), Niina Haiminen(IBM Research - Thomas J. Watson Research Center), Aki S. Havulinna(Finnish Institute for Health and Welfare), Michael Inouye(British Heart Foundation), Qiyun Zhu(University of California San Diego), Veikko Salomaa(Finnish Institute for Health and Welfare), Jeffrey D. Esko(University of California San Diego), Pedro Belda‐Ferre(University of California San Diego), Karsten Zengler(University of California San Diego), Nichole R. Klatt(University of Minnesota), Stephen Wandro(University of California San Diego), Nathan E. Lewis(University of Georgia), Bryn C. Taylor(University of California San Diego), Mohit Jain(University of California San Diego), Pekka Jousilahti(Finnish Institute for Health and Welfare), Teemu Niiranen(Edinburgh Napier University), Shi Huang(University of Hong Kong), Yujie Zhang(University of California San Diego), Ho‐Cheol Kim(Intel (United States)), Luca Schifanella(University of Minnesota Medical Center), Thomas Mandel Clausen(University of Hawaiʻi at Mānoa), Austin D. Swafford(University of California San Diego)
bioRxiv (Cold Spring Harbor Laboratory)
August 18, 2020
Cited by 37


Related Papers